Xeris Biopharma (XERS) Short Interest Ratio & Short Volume → Collapse of the Petrodollar (From Colonial Metals) (Ad) Free XERS Stock Alerts $2.33 -0.03 (-1.27%) (As of 06/7/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Xeris Biopharma Short Interest DataCurrent Short Interest10,790,000 sharesPrevious Short Interest9,640,000 sharesChange Vs. Previous Month+11.93%Dollar Volume Sold Short$21.36 millionShort Interest Ratio6.4 Days to CoverLast Record DateMay 15, 2024Outstanding Shares148,260,000 sharesPercentage of Shares Shorted7.28%Today's Trading Volume1,811,302 sharesAverage Trading Volume1,620,402 sharesToday's Volume Vs. Average112% Short Selling Xeris Biopharma ? Sign up to receive the latest short interest report for Xeris Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartXERS Short Interest Over TimeXERS Days to Cover Over TimeXERS Percentage of Float Shorted Over Time Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Xeris Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202410,790,000 shares $21.36 million +11.9%N/A6.4 $1.98 4/30/20249,640,000 shares $16.87 million +7.8%N/A5.2 $1.75 4/15/20248,940,000 shares $16.54 million -0.5%N/A4.8 $1.85 3/31/20248,980,000 shares $19.85 million -2.8%N/A4 $2.21 3/15/20249,240,000 shares $20.61 million -4.2%N/A4 $2.23 2/29/20249,640,000 shares $29.64 million +2.3%N/A4.2 $3.08 Get the Latest News and Ratings for XERS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. 2/15/20249,420,000 shares $30.24 million +0.2%N/A4.6 $3.21 1/31/20249,400,000 shares $23.12 million -9.7%N/A4.7 $2.46 1/15/202410,410,000 shares $28.84 million +8.3%N/A5.5 $2.77 12/31/20239,610,000 shares $22.58 million +18.4%N/A6.6 $2.35 12/15/20238,120,000 shares $16.40 million -1.2%N/A6.2 $2.02 11/30/20238,220,000 shares $15.29 million -8.2%N/A7 $1.86 11/15/20238,950,000 shares $13.16 million +14.9%N/A8.1 $1.47 10/31/20237,790,000 shares $14.26 million +2.4%N/A8.4 $1.83 10/15/20237,610,000 shares $12.02 million -4.0%N/A8 $1.58 9/30/20237,930,000 shares $14.75 million +0.6%N/A8.4 $1.86 9/15/20237,880,000 shares $15.76 million +6.2%N/A7.5 $2.00 8/31/20237,420,000 shares $16.84 million -12.9%N/A6.9 $2.27 8/15/20238,520,000 shares $19.00 million +2.7%N/A7.8 $2.23 7/31/20238,300,000 shares $21.66 million -2.6%N/A7.1 $2.61 7/15/20238,520,000 shares $21.64 million +0.4%N/A7.2 $2.54 6/30/20238,490,000 shares $22.24 million -5.0%N/A6.5 $2.62 6/15/20238,940,000 shares $24.23 million +13.6%N/A6.7 $2.71 5/31/20237,870,000 shares $20.15 million -5.5%N/A6.2 $2.56 5/15/20238,330,000 shares $23.66 million -1.9%N/A6.3 $2.84 4/30/20238,490,000 shares $19.19 million +6.3%N/A6.9 $2.26 4/15/20237,990,000 shares $17.34 million +2.0%N/A7 $2.17 3/31/20237,830,000 shares $12.76 million -5.4%N/A6.7 $1.63 3/15/20238,280,000 shares $10.76 million +20.9%N/A7.6 $1.30 2/28/20236,850,000 shares $9.45 million +13.4%N/A6.9 $1.38 2/15/20236,040,000 shares $7.61 million -6.9%N/A6.8 $1.26 1/31/20236,490,000 shares $8.05 million +9.1%N/A7.7 $1.24 1/15/20235,950,000 shares $7.62 million +1.9%N/A6.8 $1.28 12/30/20225,840,000 shares $7.77 million +2.5%N/A6.5 $1.33 12/15/20225,700,000 shares $7.64 million -0.7%N/A7.3 $1.34 11/30/20225,740,000 shares $8.61 million -9.5%N/A7 $1.50 11/15/20226,340,000 shares $8.81 million +0.8%N/A7.7 $1.39 10/31/20226,290,000 shares $10.06 million +0.8%N/A7.6 $1.60 10/15/20226,240,000 shares $7.61 million -5.5%N/A7.2 $1.22 9/30/20226,600,000 shares $10.30 million -21.6%N/A8 $1.56Gold Set to EXPLODE! (Ad)The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing demand from Central Banks and billionaires to EXPLODE! The elites are buying up gold like nothing we've seen before… Click here now to download the free Precious Metals Buying Guide. 9/15/20228,420,000 shares $15.07 million -8.1%N/A8 $1.79 8/31/20229,160,000 shares $15.30 million -4.8%N/A8.3 $1.67 8/15/20229,620,000 shares $18.18 million -7.1%N/A7.5 $1.89 7/31/202210,350,000 shares $14.70 million +4.9%N/A6.1 $1.42 7/15/20229,870,000 shares $14.11 million -3.3%N/A5.5 $1.43 6/30/202210,210,000 shares $15.72 million +64.7%N/A5.6 $1.54 6/15/20226,200,000 shares $10.91 million -8.3%N/A3.3 $1.76 5/31/20226,760,000 shares $14.94 million +9.0%N/A3.7 $2.21 5/15/20226,200,000 shares $10.60 million +14.6%N/A3.4 $1.71 4/30/20225,410,000 shares $13.20 million +20.2%N/A3.3 $2.44 4/15/20224,500,000 shares $11.03 million +12.8%N/A2.6 $2.45 3/31/20223,990,000 shares $10.21 million -23.4%N/A2.1 $2.56 3/15/20225,210,000 shares $13.91 million -1.7%N/A1.7 $2.67 2/28/20225,300,000 shares $12.61 million -17.3%N/A1.8 $2.38 2/15/20226,410,000 shares $16.47 million -3.5%N/A2.1 $2.57 1/31/20226,640,000 shares $14.01 million +41.6%N/A2.1 $2.11 1/15/20224,690,000 shares $10.41 million +27.5%N/A1.5 $2.22 12/31/20213,680,000 shares $10.78 million +4.3%N/A0 $2.93 12/15/20213,530,000 shares $8.01 million +16.1%N/A1.9 $2.27 11/30/20213,040,000 shares $6.35 million -30.9%N/A1.8 $2.09 11/15/20214,400,000 shares $10.91 million +14.6%N/A2.4 $2.48 10/29/20213,840,000 shares $7.14 million +13.6%N/A1.1 $1.86 10/15/20213,380,000 shares $6.76 million -17.2%N/A1 $2.00 9/30/20214,080,000 shares $10.00 million -5.1%N/A1.2 $2.45 9/15/20214,300,000 shares $10.97 million -12.1%6.6%1.2 $2.55 8/31/20214,890,000 shares $13.50 million +9.9%7.6%1.2 $2.76 8/13/20214,450,000 shares $10.32 million -17.3%6.9%1 $2.32 7/30/20215,380,000 shares $16.52 million +0.6%8.2%1.8 $3.07 7/15/20215,350,000 shares $18.89 million -60.1%8.3%1.8 $3.53 6/30/202113,400,000 shares $54.54 million -13.9%20.7%4.4 $4.07 6/15/202115,570,000 shares $64.46 million +1.8%24.0%5.4 $4.14 5/28/202115,290,000 shares $47.70 million +0.1%23.6%5.2 $3.12 5/14/202115,270,000 shares $48.71 million +14.4%N/A6.4 $3.19 4/30/202113,350,000 shares $51.66 million -1.6%N/A5.3 $3.87 4/15/202113,560,000 shares $55.19 million -1.1%N/A5.2 $4.07 3/31/202113,710,000 shares $57.72 million +29.1%N/A5 $4.21 3/15/202110,620,000 shares $51.08 million +24.8%N/A3.9 $4.81 2/26/20218,510,000 shares $46.08 million +44.5%N/A3.6 $5.42 2/12/20215,890,000 shares $39.05 million +22.0%N/A2.7 $6.63 1/29/20214,830,000 shares $25.16 million -10.6%N/A2.4 $5.21 1/15/20215,400,000 shares $31.00 million +6.3%N/A3.1 $5.74 12/31/20205,080,000 shares $25.96 million -3.8%N/A2.9 $5.11 12/15/20205,280,000 shares $24.50 million -22.8%N/A3.1 $4.64 11/30/20206,840,000 shares $30.99 million -53.8%N/A3.5 $4.53 10/30/202014,500,000 shares $71.34 million -18.0%N/A4.6 $4.92 10/15/202017,680,000 shares $94.94 million +0.9%N/A5.1 $5.37 9/30/202017,530,000 shares $103.95 million +9.5%N/A4.7 $5.93 9/15/202016,010,000 shares $88.86 million -3.7%N/A3.7 $5.55 8/31/202016,620,000 shares $78.11 million +9.2%N/A4.3 $4.70 8/14/202015,220,000 shares $63.77 million +14.6%N/A4.7 $4.19Top 5 AI Stocks to Buy for 2024 (Ad)The electric vehicle boom is accelerating – and fast.Click to View The 5 Best AI Stocks to Invest In 7/31/202013,280,000 shares $37.98 million +17.8%N/A5.7 $2.86 7/15/202011,270,000 shares $31.89 million +78.3%N/A5.8 $2.83 6/30/20206,320,000 shares $16.81 million +354.7%N/A4.3 $2.66 6/15/20201,390,000 shares $6.27 million -0.7%N/A2.4 $4.51 5/29/20201,400,000 shares $7.49 million -40.2%N/A2.2 $5.35 5/15/20202,340,000 shares $8.85 million +10.4%N/A3.6 $3.78 4/30/20202,120,000 shares $5.72 million +16.5%N/A2.9 $2.70 4/15/20201,820,000 shares $3.20 million +5.2%N/A3 $1.76 3/31/20201,730,000 shares $3.37 million +9.4%N/A3.1 $1.95 3/13/20201,582,100 shares $3.10 million +4.8%7.0%2.6 $1.96 2/28/20201,510,000 shares $2.52 million +18.9%6.6%3 $1.67 2/14/20201,270,000 shares $2.55 million -40.4%5.6%2.9 $2.01 1/31/20202,130,000 shares $8.20 million -2.3%9.3%8.8 $3.85 1/15/20202,180,000 shares $9.44 million +3.8%9.6%10.2 $4.33 12/31/20192,100,000 shares $12.08 million -7.1%9.2%10.6 $5.75 8/15/20191,721,400 shares $19.28 million -5.1%7.7%8.2 $11.20 XERS Short Interest - Frequently Asked Questions What is Xeris Biopharma's current short interest? Short interest is the volume of Xeris Biopharma shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 10,790,000 shares of XERS short. Learn More on Xeris Biopharma's current short interest. What is a good short interest ratio for Xeris Biopharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. XERS shares currently have a short interest ratio of 6.0. Learn More on Xeris Biopharma's short interest ratio. Is Xeris Biopharma's short interest increasing or decreasing? Xeris Biopharma saw a increase in short interest in May. As of May 15th, there was short interest totaling 10,790,000 shares, an increase of 11.9% from the previous total of 9,640,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Xeris Biopharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Xeris Biopharma: Veru Inc. (8.65%), Akero Therapeutics, Inc. (12.05%), MannKind Co. (13.13%), Calliditas Therapeutics AB (publ) (0.03%), Day One Biopharmaceuticals, Inc. (17.50%), AbCellera Biologics Inc. (9.58%), Mirum Pharmaceuticals, Inc. (18.69%), Prothena Co. plc (12.11%), Collegium Pharmaceutical, Inc. (21.67%), Enliven Therapeutics, Inc. (19.75%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Xeris Biopharma stock? Short selling XERS is an investing strategy that aims to generate trading profit from Xeris Biopharma as its price is falling. XERS shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Xeris Biopharma? A short squeeze for Xeris Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of XERS, which in turn drives the price of the stock up even further. How often is Xeris Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including XERS, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: VERU Short Interest Data AKRO Short Interest Data MNKD Short Interest Data CALT Short Interest Data DAWN Short Interest Data ABCL Short Interest Data MIRM Short Interest Data PRTA Short Interest Data COLL Short Interest Data ELVN Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:XERS) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.